244 related articles for article (PubMed ID: 11952770)
1. Topiramate in patients with learning disability and refractory epilepsy.
Kelly K; Stephen LJ; Sills GJ; Brodie MJ
Epilepsia; 2002 Apr; 43(4):399-402. PubMed ID: 11952770
[TBL] [Abstract][Full Text] [Related]
2. Topiramate in refractory epilepsy: a prospective observational study.
Stephen LJ; Sills GJ; Brodie MJ
Epilepsia; 2000 Aug; 41(8):977-80. PubMed ID: 10961624
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of adjunctive topiramate in refractory partial epilepsy.
Peeters K; Adriaenssen I; Wapenaar R; Neto W; Pledger G
Acta Neurol Scand; 2003 Jul; 108(1):9-15. PubMed ID: 12807387
[TBL] [Abstract][Full Text] [Related]
4. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group.
Abou-Khalil B
Epilepsia; 2000; 41(S1):72-6. PubMed ID: 10768305
[TBL] [Abstract][Full Text] [Related]
5. Topiramate and metabolic acidosis in pediatric epilepsy.
Takeoka M; Holmes GL; Thiele E; Bourgeois BF; Helmers SL; Duffy FH; Riviello JJ
Epilepsia; 2001 Mar; 42(3):387-92. PubMed ID: 11442157
[TBL] [Abstract][Full Text] [Related]
6. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy.
Ben-Menachem E; Sander JW; Stefan H; Schwalen S; Schäuble B
Clin Ther; 2008 Jul; 30(7):1180-95. PubMed ID: 18691980
[TBL] [Abstract][Full Text] [Related]
7. Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy.
Schreiner A; Stollhoff K; Ossig W; Unkelbach S; Lüer W; Bogdanow M; Schauble B;
Acta Neurol Scand; 2009 May; 119(5):304-12. PubMed ID: 19133865
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial.
Ramsay E; Faught E; Krumholz A; Naritoku D; Privitera M; Schwarzman L; Mao L; Wiegand F; Hulihan J;
Epilepsia; 2010 Oct; 51(10):1970-7. PubMed ID: 20633037
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy.
Tassinari CA; Michelucci R; Chauvel P; Chodkiewicz J; Shorvon S; Henriksen O; Dam M; Reife R; Pledger G; Karim R
Epilepsia; 1996 Aug; 37(8):763-8. PubMed ID: 8764816
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with topiramate dosing and serum levels in patients with epilepsy.
Zanotta N; Raggi ME; Radice L; Degrate A; Bresolin N; Zucca C
Seizure; 2006 Mar; 15(2):86-92. PubMed ID: 16406695
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
[TBL] [Abstract][Full Text] [Related]
12. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting.
Helmstaedter C; Witt JA
Epilepsy Behav; 2013 Feb; 26(2):182-7. PubMed ID: 23318473
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures.
Ben-Menachem E; Henriksen O; Dam M; Mikkelsen M; Schmidt D; Reid S; Reife R; Kramer L; Pledger G; Karim R
Epilepsia; 1996 Jun; 37(6):539-43. PubMed ID: 8641230
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy.
Lhatoo SD; Wong IC; Sander JW
Epilepsia; 2000 Mar; 41(3):338-41. PubMed ID: 10714407
[TBL] [Abstract][Full Text] [Related]
15. Topiramate: efficacy and tolerability in children according to epilepsy syndromes.
Mikaeloff Y; de Saint-Martin A; Mancini J; Peudenier S; Pedespan JM; Vallée L; Motte J; Bourgeois M; Arzimanoglou A; Dulac O; Chiron C
Epilepsy Res; 2003 Mar; 53(3):225-32. PubMed ID: 12694931
[TBL] [Abstract][Full Text] [Related]
16. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response.
Ferrari AR; Guerrini R; Gatti G; Alessandrì MG; Bonanni P; Perucca E
Ther Drug Monit; 2003 Dec; 25(6):700-8. PubMed ID: 14639056
[TBL] [Abstract][Full Text] [Related]
17. Preliminary observations on topiramate in pediatric epilepsies.
Glauser TA
Epilepsia; 1997; 38 Suppl 1():S37-41. PubMed ID: 9092958
[TBL] [Abstract][Full Text] [Related]
18. Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study.
Coppola G; Caliendo G; Veggiotti P; Romeo A; Tortorella G; De Marco P; Pascotto A
Epilepsy Res; 2002 Sep; 51(1-2):147-53. PubMed ID: 12350390
[TBL] [Abstract][Full Text] [Related]
19. Topiramate in add-on therapy: results from an open-label, observational study.
Krakow K; Lengler U; Rettig K; Schreiner A; Schauble B;
Seizure; 2007 Oct; 16(7):593-600. PubMed ID: 17543544
[TBL] [Abstract][Full Text] [Related]
20. The effects of adjunctive topiramate on cognitive function in patients with epilepsy.
Lee S; Sziklas V; Andermann F; Farnham S; Risse G; Gustafson M; Gates J; Penovich P; Al-Asmi A; Dubeau F; Jones-Gotman M
Epilepsia; 2003 Mar; 44(3):339-47. PubMed ID: 12614389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
